Screener
Palvella Therapeutics PVLA Net Interest Income
Net Interest Income at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNet.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest expense – royalty agreement | (2,039) | (1,215) |
| Fair value adjustments on derivative liabilities – royalty agreement | (116) | (75) |
| Fair value adjustments on derivative liabilities – contingent value right liability | 202 | — |
| Interest income, net | 1,073 | 752 |
| Other income (expense), net | (32) | 224 |
| Loss before income taxes | (15,767) | (8,185) |
| Income tax benefit (expense) | — | — |
| Net loss | $(15,767) | $(8,185) |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's net interest income?
- Palvella Therapeutics (PVLA) reported net interest income of $1.07M in Q1 2026.
- How has Palvella Therapeutics's net interest income changed year-over-year?
- Palvella Therapeutics's net interest income increased by 42.7% year-over-year, from $752K to $1.07M.
- What does net interest income mean?
- This is the difference between the interest income generated from interest-bearing assets and the interest expense paid on liabilities. It serves as a fundamental measure of the company's efficiency in managing its capital structure and liquidity. A positive value indicates that the company earns more on its cash and investments than it pays on its debt obligations.
Ask your AI about Palvella Therapeutics's net interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude